Stifel raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $90.00 (from $77.00) while maintaining a Buy rating.

Analyst PT Change

Ultragenyx Pharma (RARE) PT Raised to $59 at Morgan StanleyAugust 7, 2018 7:14 AM Ultragenyx Pharma (RARE) PT Raised to $80 at WedbushAugust 6, 2018 7:50 AM Ultragenyx Pharma (RARE) PT Raised to $85 at Piper JaffrayAugust 3, 2018 6:01 AM Ultragenyx Pharma (RARE) PT Raised to $92 at BarclaysAugust 3, 2018 5:15 AM Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 LossAugust 2, 2018 5:06 PM